Stockscreener 앱 받기
18.14
2.54%
0.45
시장 영업 전:
18.04
-0.10
-0.55%
전일 마감가:
$17.69
열려 있는:
$17.805
하루 거래량:
656.28K
Relative Volume:
0.31
시가총액:
$1.30B
수익:
-
순이익/손실:
$-213.70M
주가수익비율:
-5.451
EPS:
-3.3278
순현금흐름:
$-185.90M
1주 성능:
-0.44%
1개월 성능:
+20.69%
6개월 성능:
-69.62%
1년 성능:
-54.99%
1일 변동 폭
$17.64
$18.18
1주일 범위
$17.00
$18.23
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.14 | 1.27B | 0 | -213.70M | -185.90M | -3.3278 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
What is HC Wainwright's Estimate for MLTX FY2027 Earnings? - MarketBeat
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a 34.94% Upside in the Biotech Sphere - DirectorsTalk Interviews
Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential - Investing.com
MoonLake Immunotherapeutics price target raised to $40 from $32 at H.C. Wainwright - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed? - simplywall.st
MLTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Royal Bank Of Canada Boosts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $13.00 - MarketBeat
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Finviz
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
RBC Raises Price Target on MoonLake Immunotherapeutics to $13 From $12, Keeps Sector Perform, Speculative Risk - marketscreener.com
Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results - Investing.com
MoonLake Immunotherapeutics price target raised to $35 from $30 at Oppenheimer - TipRanks
Stifel Downgrades MoonLake Immunotherapeutics(MLTX.US) to Hold Rating, Cuts Target Price to $19 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Share Price Performance And Premium P/B Ratio - Yahoo Finance
MoonLake’s Sonelokimab Data Sharpens Risk Reward Profile Before Phase 3 - simplywall.st
MoonLake Immunotherapeutics (MLTX) Is Down 6.7% After Mixed 2025 Results And AxSpA Data UpdateWhat's Changed - Yahoo Finance
MoonLake shares climb on encouraging AXSPA trial results - MSN
Goldman Sachs Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $11 - 富途牛牛
MoonLake Immunotherapeutics price target raised to $11 from $10 at Goldman Sachs - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Decoding MoonLake Immunotherapeutics (MLTX): A Strategic SWOT Insight - GuruFocus
(MLTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results - MarketBeat
Quarterly Earnings: Is MoonLake Immunotherapeutics stock a falling knife or bargain buyJuly 2025 Volume & Consistent Return Strategy Ideas - baoquankhu1.vn
Lifesci Capital Has Optimistic Outlook of MLTX Q4 Earnings - MarketBeat
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Unveiling a 12.8% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 S-OLARIS Trial Results - simplywall.st
MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX) - Seeking Alpha
MoonLake turns the tables on sonelokimab with positive data - The Pharma Letter
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $6 - 富途牛牛
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $34 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Price Target Increased by 11.25% to 22.30 - Nasdaq
Oppenheimer Adjusts Price Target on MoonLake Immunotherapeutics to $35 From $30, Maintains Outperform Rating - marketscreener.com
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $20 - 富途牛牛
Needham & Company LLC Issues Positive Forecast for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Raised to $30.00 - MarketBeat
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins - MarketBeat
MoonLake Expects To File Sonelokimab For HS Later In 2026 - Citeline News & Insights
MoonLake touts Phase II sonelokimab results in spine disease study - FirstWord Pharma
Needham Raises MoonLake Immunotherapeutics' Price Target to $25 From $20, Buy Rating Kept - marketscreener.com
MoonLake stock surges 63% after InvestingPro Fair Value call By Investing.com - Investing.com UK
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy, safety, and financial runway - TradingView
MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data ReleaseHas The Bull Case Changed? - simplywall.st
MLTX: BLA submission for SLK in HS on track, supported by robust efficacy and safety data - TradingView
MoonLake's sonelokimab shows strong Phase II efficacy in axSpA, challenging UCB’s Bimzelx - European Biotechnology Magazine
Why Is MoonLake Immunotherapeutics Stock Trading Higher TodayMoonLake (NASDAQ:MLTX) - Benzinga
MoonLake stock surges on positive axSpA trial data By Investing.com - Investing.com South Africa
MoonLake stock surges on positive axSpA trial data - Investing.com India
US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris - Bloomberg
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):